These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation. Ellmark P; Mangsbo SM; Furebring C; Norlén P; Tötterman TH Cancer Immunol Immunother; 2017 Jan; 66(1):1-7. PubMed ID: 27714433 [TBL] [Abstract][Full Text] [Related]
5. When fat is favorable: the unexpected relationship between obesity and response to immunotherapy. Jin J; Stabile LP Immunotherapy; 2020 Oct; 12(14):1035-1039. PubMed ID: 32878516 [No Abstract] [Full Text] [Related]
8. Cellular Bioparticulates with Therapeutics for Cancer Immunotherapy. Wang C; Wen D; Gu Z Bioconjug Chem; 2018 Mar; 29(3):702-708. PubMed ID: 29227626 [TBL] [Abstract][Full Text] [Related]
9. Industry shows increased appetite for macrophage biology. Morrison C Nat Rev Drug Discov; 2020 May; 19(5):295-297. PubMed ID: 32303699 [No Abstract] [Full Text] [Related]
10. New Trends in Anti-Cancer Therapy: Combining Conventional Chemotherapeutics with Novel Immunomodulators. Wilson AL; Plebanski M; Stephens AN Curr Med Chem; 2018; 25(36):4758-4784. PubMed ID: 28875845 [TBL] [Abstract][Full Text] [Related]
11. New checkpoint inhibitors ride the immunotherapy tsunami. Mullard A Nat Rev Drug Discov; 2013 Jul; 12(7):489-92. PubMed ID: 23812256 [No Abstract] [Full Text] [Related]
12. First-in-class cancer therapeutic to stimulate natural killer cells. Sheridan C Nat Biotechnol; 2006 Jun; 24(6):597. PubMed ID: 16763573 [No Abstract] [Full Text] [Related]
13. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy. Dougall WC; Kurtulus S; Smyth MJ; Anderson AC Immunol Rev; 2017 Mar; 276(1):112-120. PubMed ID: 28258695 [TBL] [Abstract][Full Text] [Related]
14. Bispecific antibodies for viral immunotherapy. Nyakatura EK; Soare AY; Lai JR Hum Vaccin Immunother; 2017 Apr; 13(4):836-842. PubMed ID: 27786606 [TBL] [Abstract][Full Text] [Related]
16. IDO inhibitors move center stage in immuno-oncology. Sheridan C Nat Biotechnol; 2015 Apr; 33(4):321-2. PubMed ID: 25850038 [No Abstract] [Full Text] [Related]
17. Oncologists tap the microbiome in bid to improve immunotherapy outcomes. Mullard A Nat Rev Drug Discov; 2018 Mar; 17(3):153-155. PubMed ID: 29449710 [No Abstract] [Full Text] [Related]
18. Co-stimulatory and co-inhibitory pathways in cancer immunotherapy. O'Neill RE; Cao X Adv Cancer Res; 2019; 143():145-194. PubMed ID: 31202358 [TBL] [Abstract][Full Text] [Related]
19. The paired receptors TIGIT and DNAM-1 as targets for therapeutic antibodies. Stein N; Tsukerman P; Mandelboim O Hum Antibodies; 2017; 25(3-4):111-119. PubMed ID: 28035916 [TBL] [Abstract][Full Text] [Related]
20. Gangliosides as immunomodulators. Potapenko M; Shurin GV; de León J Adv Exp Med Biol; 2007; 601():195-203. PubMed ID: 17713006 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]